Evaluation of Tigecycline Utilization and Trends in Antibacterial Resistance from 2018 to 2021 in a Comprehensive Teaching Hospital in China

References

• Huemer M, Mairpady Shambat S, Brugger SD, Zinkernagel AS. Antibiotic resistance and persistence-Implications for human health and treatment perspectives. EMBO Rep. 2020;21(12):e51034. doi:10.15252/embr.202051034
   PubMed Web of Science ®Google Scholar
• Köck R, Becker K, Idelevich EA, et al. Prevention and control of multidrug-resistant bacteria in the Netherlands and Germany-the impact of healthcare structures. Int J Environ Res Public Health. 2020;17(7):2337. doi:10.3390/ijerph17072337
   PubMed Web of Science ®Google Scholar
• Blake KS, Choi J, Dantas G. Approaches for characterizing and tracking hospital-associated multidrug-resistant bacteria. Cell Mol Life Sci. 2021;78(6):2585–2606. doi:10.1007/s00018-020-03717-2
   PubMed Web of Science ®Google Scholar
• National Health Commission. Notice on continuing to do a good job in clinical application management of antibacterial drugs. National Health Office Medical Letter [2020, No. 8]; 2020. Available from: http://www.gov.cn/zhengce/zhengceku/2020-07/24/content_5529693.htm. Accessed February 7, 2023.
   Google Scholar
• Yaghoubi S, Zekiy AO, Krutova M, et al. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. Eur J Clin Microbiol Infect Dis. 2022;41(7):1003–1022. doi:10.1007/s10096-020-04121-1
   PubMed Web of Science ®Google Scholar
• Kaewpoowat Q, Ostrosky-Zeichner L. Tigecycline: a critical safety review. Expert Opin Drug Saf. 2015;14(2):335–342. doi:10.1517/14740338.2015.997206
   PubMed Web of Science ®Google Scholar
• Brink AJ, Bizos D, Boffard KD, et al. Guideline: appropriate use of tigecycline. S Afr Med J. 2010;100(6 Pt 2):388–394. doi:10.7196/samj.4109
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x
   PubMed Web of Science ®Google Scholar
• LiverTox. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
   Google Scholar
• Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ. In vitro activity of tigecycline against 6792 gram-negative and gram positive clinical isolates from the global tigecycline evaluation and surveillance trial (test program, 2004). Diagn Microbiol Infect Dis. 2005;52:215–227. doi:10.1016/j.diagmicrobio.2005.06.001
   PubMed Web of Science ®Google Scholar
• Zhao J, Liu Y, Liu Y, et al. Frequency and genetic determinants of tigecycline resistance in clinically isolated stenotrophomonas maltophilia in Beijing, China. Front Microbiol. 2018;9:549. doi:10.3389/fmicb.2018.00549
   PubMed Web of Science ®Google Scholar
• National Health Commission. Notice on Printing and Distributing 3 Technical Documents including Expert Consensus on Clinical Application of Carbapenems Antibacterial Drugs. National Health Office Medical Letter [2018, No. 822]; 2018. Available from: http://www.nhc.gov.cn/yzygj/s7659/201809/95f65ca473b44746b24590e94468b8ff.shtml. Accessed February 7, 2023.
   Google Scholar
• China Antimicrobial Resistance Surveillance System. National antimicrobial resistance surveillance report. CARSS; 2020. Available from: http://www.carss.Cn. Accessed February 7, 2023.
   Google Scholar
• National Health and Family Planning Commission. National action plan for containing bacterial resistance. Available from: http://www.nhc.gov.cn/yzygj/s7659/201809/95f65ca473b44746b24590e94468b8ff.shtml. Accessed 31, October 2018.
   Google Scholar
• Guidance for clinical trials of anti-bacterial drugs; 2015. Available from: https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20150403120001449.html. Accessed February 7, 2023.
   Google Scholar
• Montravers P, Dupont H, Bedos JP, Bret P; The Tigecycline Group. Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting. Intensive Care Med. 2014;40:988–997. doi:10.1007/s00134-014-3323-7
   PubMed Web of Science ®Google Scholar
• Wang X, Wang Q, Cao B, et al. Retrospective observational study from a Chinese network of the impact of combination therapy versus monotherapy on mortality from carbapenem-resistant Enterobacteriaceae bacteremia. Antimicrob Agents Chemother. 2019;63(1):e01511. doi:10.1128/AAC.01511-18
   PubMed Web of Science ®Google Scholar
• Wang H, Yu YS, Wang MG, et al. Expert consensus on the operating procedures of tigecycline in vitro drug sensitivity test. Chin J Lab Med. 2013;36(7):584–587. doi:10.3760/cma.j.issn.1009-9158.2013.07.004
   Google Scholar
• Babaei S, Haeili M. Evaluating the performance characteristics of different antimicrobial susceptibility testing methodologies for testing susceptibility of gram-negative bacteria to tigecycline. BMC Infect Dis. 2021;21(1):709. doi:10.1186/s12879-021-06338-7
   PubMed Web of Science ®Google Scholar
• Amann LF, Alraish R, Broeker A, Kaffarnik M, Wicha SG. Tigecycline dosing strategies in critically ill liver-impaired patients. Antibiotics. 2022;11(4):479. doi:10.3390/antibiotics11040479
   Google Scholar
• Levonorgestrel I. Drugs and Lactation Database (Lactmed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006.
   Google Scholar
• McKeage K, Keating GM. Tigecycline: in community-acquired pneumonia. Drugs. 2008;68(18):2633–2644. doi:10.2165/0003495-200868180-00008
   PubMed Web of Science ®Google Scholar
• Xu L, Wang YL, Du S, Chen L, Long LH, Wu Y. Efficacy and safety of tigecycline for patients with hospital-acquired pneumonia. Chemotherapy. 2016;61(6):323–330. doi:10.1159/000445425
   PubMed Web of Science ®Google Scholar
• Wang J, Pan Y, Shen J, Xu Y. The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob. 2017;16(1):24. doi:10.1186/s12941-017-0199-8
   PubMed Web of Science ®Google Scholar
• Babinchak T, Ellis-Grosse E, Dartois N, et al. The efficacy and safety of tigecycline for the treatment of complicated intraabdominal infections: analysis of pooled clinical trial data. Clin Infect Dis. 2005;41:354–367. doi:10.1086/431676
   PubMed Web of Science ®Google Scholar
• Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin structure infections: results of 2 double-blind Phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005;41:341–353. doi:10.1086/431675
   PubMed Web of Science ®Google Scholar
• Moghnieh RA, Abdallah DI, Fawaz IA, et al. Prescription patterns for tigecycline in severely ill patients for Non-FDA approved indications in a developing country: a compromised outcome. Front Microbiol. 2017;8:497. doi:10.3389/fmicb.2017.00497
   PubMed Web of Science ®Google Scholar
• Guan X, He L, Hu B, et al.; Chinese XDR Consensus Working Group. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement. Clin Microbiol Infect. 2016;Suppl 1. S15–S25. doi:10.1016/j.cmi.2015.11.004
   PubMedGoogle Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated Pneumonia: 2016 clinical practice guidelines by the infectious disease Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):61–111. doi:10.1093/cid/ciw353
   PubMed Web of Science ®Google Scholar
• Liu YN. Whether tigecycline can be used to treat hospital-acquired pneumonia caused by Acinetobacter. Chin Tuber Respir Dis. 2016;39(10):753–754. doi:10.3389/fmed.2022.772372
   Google Scholar
• Meagher AK, Ambrose PG, Grasela TH, et al. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis. 2005;5:333–340. doi:10.1086/431674
   Google Scholar
• Liu YX, Le KJ, Shi HY, et al. Efficacy and safety of tigecycline for complicated urinary tract infection: a systematic review. Transl Androl Urol. 2021;10(1):292–299. doi:10.1086/431674
   PubMed Web of Science ®Google Scholar
• Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem resistant and extensively drug-resistant Acineto bacter baumannii infections. Drugs. 2014;74:1315–1333. doi:10.1007/s40265-014-0267-8
   PubMed Web of Science ®Google Scholar
• Lemos EV, de la Hoz FP, Einarson TR, et al. Carbapenem resistance and mortality in patients with Acineto bacter baumannii infection: systematic review and meta-analysis. Clin Microbiol Infect. 2014;20(5):416–423. doi:10.1111/1469-0691.12363
   PubMed Web of Science ®Google Scholar
• US FDA. FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning; 2013. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-increased-risk-death-iv-antibacterial-tygacil-tigecycline. Accessed August 3, 2020.
   Google Scholar